In his weekly clinical update, Dr. Griffin discusses progress toward measles elimination, risk of severe coronavirus disease 2019 despite vaccination in patients requiring treatment with immune-suppressive drugs, symptoms, viral loads, and rebound among COVID-19 outpatients treated with nirmatrelvir/ritonavir compared to propensity score matched untreated individuals, late administration and corticosteroid usage explain inefficacy in COVID-19 convalescent plasma trial, higher-dose fluvoxamine and time to sustained recovery in outpatients with COVID-19, recombinant C1 inhibitor in the prevention of severe COVID-19, and Epstein-Barr virus reactivation is not causative for post-COVID-19-syndrome in individuals with asymptomatic or mild SARS-CoV-2 disease course.

In his weekly clinical update, Dr. Griffin discusses coverage with selected vaccines and exemption from school vaccine requirements among children in kindergarten, seasonality of endemic COVID-19, mRNA SARS-CoV-2 vaccination before vs during pregnancy and omicron infection among infants, extracting symptoms from free-text responses using ChatGPT among COVID-19 cases in Hong Kong, SARS-CoV-2 virologic rebound with nirmatrelvir–ritonavir therapy, optimization of antiviral therapy in immunocompromised COVID-19 patients, a study to learn about the study medicines (nirmatrelvir plus ritonavir) in people aged 12 years or older with COVID-19 and a compromised immune system, evaluation of the safety profile and therapeutic efficacy of Remdesivir in children with SARS-CoV-2 infection, effect of neutralizing monoclonal antibody treatment on early trajectories of virologic and immunologic biomarkers in patients hospitalized with COVID-19, and SARS-CoV-2 virologic rebound with nirmatrelvir–ritonavir therapy.

In his weekly clinical update, Dr. Griffin discusses stress in America 2023, CDC expanding testing of international air traveler samples to include flu, RSV, and other respiratory viruses, missed opportunities for preventing congenital syphilis, intrinsic and effective severity of COVID-19 cases infected with the ancestral strain and omicron BA.2 variant in Hong Kong, T-cell immunity against severe acute respiratory syndrome coronavirus 2 measured by an interferon-γ release assay is strongly associated with patient outcomes in vaccinated persons hospitalized with delta or omicron variants, masks during pandemics caused by respiratory pathogens, behavioral factors and SARS-CoV-2 transmission heterogeneity within a household cohort in Costa Rica, convalescent plasma for Covid-19–induced ARDS in mechanically ventilated patients, and olfactory and gustatory function 3 years after mild COVID-19.

Klaus Früh visits the Incubator to discuss his career and his work on cytomegalovirus-vectored vaccines which are unique in their ability to persistently maintain an immune shield of effector memory T cells, including highly unconventional MHC-II and MHC-E restricted CD8+ T cells.

In his weekly clinical update, Dr. Griffin discusses health worker–perceived working conditions and symptoms of poor mental health, Mpox neutralizing antibodies at 6 months from mpox infection or MVA-BN vaccination, newborn and early infant outcomes following maternal COVID-19 vaccination during pregnancy, duration of SARS-CoV-2 culturable virus shedding in children, prescribing outcomes in outpatients treated with nirmatrelvir–ritonavir for COVID-19 in an interdisciplinary community clinic, Nirmatrelvir and molnupiravir and post-COVID-19 condition in older patients, optimal duration of systemic corticosteroids in COVID-19 treatment, association between Guillain-Barré syndrome and COVID-19 infection and vaccination, SARS-CoV-2 infection correlates with male benign prostatic hyperplasia deterioration, Transplanting candidates with COVID-19, and favorable experience of transplant strategy including liver grafts from COVID-19 donors.